Display options
Cite
Veysey-Smith R, Moore AR, Murugesan SV, et al. Effects of Proton Pump Inhibitor Therapy, . Front Endocrinol (Lausanne). 2021;12:741887doi: 10.3389/fendo.2021.741887.
Veysey-Smith, R., Moore, A. R., Murugesan, S. V., Tiszlavicz, L., Dockray, G. J., Varro, A., & Pritchard, D. M. (2021). Effects of Proton Pump Inhibitor Therapy, . Frontiers in endocrinology, 12741887. https://doi.org/10.3389/fendo.2021.741887
Veysey-Smith, Reuben, et al. "Effects of Proton Pump Inhibitor Therapy, ." Frontiers in endocrinology vol. 12 (2021): 741887. doi: https://doi.org/10.3389/fendo.2021.741887
Veysey-Smith R, Moore AR, Murugesan SV, Tiszlavicz L, Dockray GJ, Varro A, Pritchard DM. Effects of Proton Pump Inhibitor Therapy, . Front Endocrinol (Lausanne). 2021 Nov 18;12:741887. doi: 10.3389/fendo.2021.741887. eCollection 2021. PMID: 34867785; PMCID: PMC8637328.
Copy Download .nbib Format: NLM
Share it on

Front Endocrinol (Lausanne). 2021 Nov 18;12:741887. doi: 10.3389/fendo.2021.741887. eCollection 2021.

Effects of Proton Pump Inhibitor Therapy, .

Frontiers in endocrinology

Reuben Veysey-Smith, Andrew R Moore, Senthil V Murugesan, Laszlo Tiszlavicz, Graham J Dockray, Andrea Varro, D Mark Pritchard

Affiliations

  1. Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
  2. Gastroenterology Department, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom.
  3. Gastroenterology Department, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom.
  4. Department of Pathology, University of Szeged, Szeged, Hungary.

PMID: 34867785 PMCID: PMC8637328 DOI: 10.3389/fendo.2021.741887

Abstract

BACKGROUND: Hypergastrinaemia occasionally indicates the presence of a gastrinoma. However it is much more commonly associated with various benign causes including proton pump inhibitor (PPI) use,

MATERIALS AND METHODS: Fasting serum gastrin concentrations were measured by radioimmunoassay in 1,400 patients attending for diagnostic oesophagogastro-duodenoscopy. After exclusions, 982 patients were divided into four groups and their results analysed. We compared gastrin concentrations in normal patients (no

RESULTS: Median fasting gastrin concentration in the normal group was 20pM and was significantly increased in PPI users (46pM, p<0.0001), patients with active

CONCLUSIONS: PPI use,

Copyright © 2021 Veysey-Smith, Moore, Murugesan, Tiszlavicz, Dockray, Varro and Pritchard.

Keywords: Helicobacter pylori; atrophic gastritis; gastrin; oesophagogastroduodenoscopy; proton pump inhibitor

Conflict of interest statement

DMP has served as a speaker, a consultant and/or advisory board member for Ipsen, Advanced Accelerator Applications and Mayoly Spindler laboratories and has received research funding to investigate ga

References

  1. Peptides. 2016 May;79:83-94 - PubMed
  2. Dig Liver Dis. 2005 Jan;37(1):10-22 - PubMed
  3. Gastroenterology. 2011 May;140(5):1444-53 - PubMed
  4. Gastroenterology. 2003 Mar;124(3):615-25 - PubMed
  5. Compr Physiol. 2019 Dec 18;10(1):197-228 - PubMed
  6. Gastroenterology. 2000 Jan;118(1):36-47 - PubMed
  7. Aliment Pharmacol Ther. 2012 Jul;36(1):37-47 - PubMed
  8. Korean J Intern Med. 1999 Jan;14(1):15-20 - PubMed
  9. Am J Gastroenterol. 2010 May;105(5):1039-45 - PubMed
  10. Aliment Pharmacol Ther. 2015 Sep;42(6):649-63 - PubMed
  11. PLoS Pathog. 2017 Nov 2;13(11):e1006653 - PubMed
  12. Data Brief. 2019 Apr 01;24:103886 - PubMed
  13. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):4-19 - PubMed
  14. World J Gastroenterol. 2009 Jan 7;15(1):1-16 - PubMed
  15. Aliment Pharmacol Ther. 2009 May 15;29(10):1055-68 - PubMed
  16. J Clin Gastroenterol. 2020 Mar;54(3):227-234 - PubMed
  17. Annu Rev Physiol. 2001;63:119-39 - PubMed
  18. Cancer Res. 2003 Mar 1;63(5):942-50 - PubMed
  19. Gastroenterology. 1997 Mar;112(3):707-17 - PubMed
  20. Digestion. 2001;64(4):205-13 - PubMed
  21. J Gastroenterol. 2002;37(2):77-86 - PubMed
  22. Ann Med. 1995 Oct;27(5):569-73 - PubMed

Publication Types

Grant support